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Abstract: Magnetically labelled cells are used for in vivo cell tracking by MRI, used for 
the clinical translation of cell-base therapies. Studies involving magnetic labelled cells may 
include separation of labelled cells, targeted delivery and controlled release of drugs, 
contrast enhanced MRI and magnetic hyperthermia for the in situ ablation of tumours. 
Dextran-coated super-paramagnetic iron oxide (SPIO) ferumoxides are used clinically as 
an MR contrast agents primarily for hepatic imaging. The material is also widely used for 
in vitro cell labelling, as are other SPIO-based particles. Our results on the uptake by 
human cancer cell lines of ferumoxides indicate that electroporation in the presence of 
protamine sulphate (PS) results in rapid high uptake of SPIO nanoparticles (SPIONs) by 
parenchymal tumour cells without significant impairment of cell viability. Quantitative 
determination of cellular iron uptake performed by colorimetric assay is in agreement with 
data from the literature. These results on intracellular iron content together with the 
intracellular distribution of SPIONs by magnetic force microscopy (MFM) following  
in vitro uptake by parenchymal tumour cells confirm the potential of this technique for 
clinical tumour cell detection and destruction.  
Keywords: magnetic nanoparticles; superparamagnetic; SPIONs; nanomedicine; magnetic 
cell labelling; magnetic force microscopy  
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1. Introduction 
All materials are magnetic to some extent, with their response depending on their atomic  
structure and temperature. They can be conveniently classified in terms of their volumetric magnetic 
susceptibility, χ, where M = χH describes the (volumetric) magnetization M induced in a material by 
magnetic field (strength), H, with the material (relative) permeability, μr, being defined as μr = (1 + χ). 
In SI units, χ is dimensionless, and both M and H are expressed in Am−1. Most materials display little 
magnetism and, even then, only in the presence of an applied field; these are classified either as 
paramagnets, for which χ falls in the range 10−6 to 10−1, or diamagnets, with χ being in the range −10−6 
to −10−3. However, some materials exhibit ordered magnetic states and are magnetic even without an 
applied field. These are classified as ferromagnets, ferrimagnets and antiferromagnets, where the prefix 
refers to the nature of the coupling interaction between the electrons within the material. This coupling 
can give rise to large spontaneous magnetizations; in ferromagnets, M is typically 104 times larger than 
would otherwise be the case. 
The magnetic properties in ferromagnetic materials are the result of aligned unpaired electron spins. 
For these materials, magnetization is evident even in the absence of an external field. The transition 
between two magnetic domains (so-called Weiss domains) is referred to as a Bloch wall. At the 
nanometre scale (of the order of tens of nanometres or less, e.g., ~14 nm), the formation of Bloch walls 
becomes thermodynamically unfavourable, leading to the formation of single domain crystals, which 
are classified as superparamagnetic. The term superparamagnetic refers to the characteristic strong 
paramagnetic nature of the particles at this scale. Paramagnetic materials are distinguished by the 
tendency of their atomic magnetic dipoles to align with an external magnetic field, their small positive 
magnetic susceptibility (i.e., ability to strengthen the field they are in) and their random orientation in 
the absence of a magnetic field (due to Brownian fluctuations). Superparamagnetic iron oxide (SPIO) 
nanoparticles have much larger susceptibilities (compared with strictly paramagnetic materials), as the 
entire crystal aligns with the applied field, due to its single crystal nature [1]. 
Magnetic nanoparticles offer a lot of attractive possibilities in biomedicine [2,3], and magnetic cell 
labelling is considered essential for the translation of cell-base therapies from the laboratory to clinical 
studies. Examples include magnetic separation of labelled cells and biological entities [4], targeted 
delivery and controlled release of drugs [5,6], magnetic hyperthermia for the in situ ablation of 
tumours [7] and contrast enhanced MRI [8–10]. Molecular and cellular magnetic resonance (MR) 
imaging is a rapidly growing field that aims to visualize targeted macromolecules or cells in living 
organisms by the use of superparamagnetic iron oxide (SPIO) nanoparticles (SPIONs) [1,11]. MR cell 
tracking, with its excellent spatial resolution, can be used as a non-invasive tool to provide unique 
information on the dynamics of cell movements in vivo. It is likely that MR cell tracking will be used 
in the future to monitor (stem) cell therapy in patients [12]. All these approaches require magnetic 
labelling of cells, as well as methods for analysis and evaluation of cell labelling [13,14]. Due to their 
biocompatibility and strong effects on T2* relaxation, iron oxide nanoparticles are now the MR 
contrast agent of choice for cell labelling [15], and several methods have been developed to 
incorporate sufficient quantities of iron oxide nanoparticles into cells [16,17].  
A variety of cells have the natural ability to internalize exogenous material by a process known as 
endocytosis. The size of material and the rate at which it is internalized is dependent on the specific 
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trans-membrane mechanism involved in the passage through the cell membrane. While specific 
cellular labelling by targeting specific binding sites on the surface of cells is possible, using SPIO 
nanoparticles coated with antibodies or other biological macromolecules, such as hormones or folic 
acid [18], our studies focused on non-specific cellular labelling. The majority of nonspecific cellular 
labelling has to date involved macrophages, as these cells are capable of efficient phagocytosis of 
exogenous/foreign particles, including micrometre-sized iron oxide particles [19]. In more general 
cases, the iron cellular uptake is not sufficient without the use of transfection agents or linking 
nanoparticles to the highly cationic HIV TAT peptide [20] or by using other physical means, such as 
magnetofection [21], electroporation [22] or sonoporation [23]. For example, cells have been 
successfully magnetically labelled by simply adding magneto-dendrimers, synthesized dendrimer 
encapsulated SPIOs [24], to the culture medium at concentrations of up to 25 µg iron/mL and 
incubation periods of one to two days.  
For cell labelling application, magnetic nanoparticles have surface modification, usually by coating 
with biocompatible molecules, e.g., dextran, polyvinyl alcohol (PVA) and phospholipids. As well as 
providing a link between the particle and the target site on a cell or molecule, coating has the 
advantage of increasing the colloidal stability of the magnetic fluid. Ferumoxide (Feridex; Berlex, 
Wayne, NJ, USA) is a dextran-coated iron oxide [25], with particles sized between 80 and 120 nm. 
Ferumoxide is an FDA approved hepatic contrast agent, because the nanoparticles are spontaneously 
internalized by phagocytes (Kupffer cells). On post-contrast MRI scans, the phagocyte-rich liver turns 
dark, while the tumour, lacking macrophages, remains iso-intense (white). In our studies, for magnetic 
pre-labelling of non-phagocytic cells and cellular MRI, Ferumoxides have been combined with other 
commercially available transfection agents (TAs), such as poly-L-lysine (PLL) (Sigma, St. Louis, MO, 
USA) and Lipofectamine Plus (Invitrogen Life Technologies, Gaithersburg, MD, USA) [26]. 
We investigated several protocols for magnetic labelling of human cancer cells with ferumoxides [25] 
utilizing transfection agents, including poly-L-lysine (PLL), poly-L-ornithine (PLO) and protamine 
sulphate (PS), and applying electroporation [27]. In this report, we describe a quantitative assessment 
of magnetically labelled cells using conventional iron uptake measurement, as well as a magnetic force 
microscopy (MFM) study, which has the capability to resolve the spatial distribution of internalized 
magnetic nanoparticles [28–30] and can also be used to estimate the true uptake by a single cell and its 
resulting magnetization. 
2. Results and Discussion 
2.1. Magnetic Labelled Cells—Efficiency and Viability  
Cells were successfully labelled by magnetic nanoparticles (IO-nPs or ferumoxides) using Prussian 
blue staining, as illustrated (Figure 1). The resulting cell labelling efficiency and cell viability for three 
labelling methods used in this study are shown in Table 1. A very high labelling efficiency (95%) was 
obtained using protamine sulphate (PS) alone, while electroporation (EP) was only capable of  
loading cells with an efficiency of 72%. When PS was added to magnetic nanoparticles solution in 
electroporation mixtures, the loading efficiency increased from 72% to 88%.  
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Figure 1. Cell labelling by electroporation and PS/electroporation: (a) stained promptly 
after electroporation (Cytospin staining); (b) stained after overnight culture. PS, protamine 
sulphate; EP, electroporation; IO-nPs, ferumoxides.  
 
Table 1. Comparison of cell labelling by transfection, electroporation and PS/electroporation 
(PS, protamine sulphate; EP, electroporation; IO-nPs, ferumoxides). 
Labelling method PS EP PS/EP 
Final concentration of IO-nPs (μg/mL) 30 100 100 
Final concentration of PS (μg/mL) 3.0 – 3.0 
Duration of procedure 14–16 h 30 min 30 min 
Labelling efficiency (%) 95 72 88 
Cell viability (A 375M) 98.73 ± 5.56 73.21 ± 7.21 89.34 ± 3.56 
With incubation of cells with PS, nanoparticle solution with PS did not significantly affect cell 
proliferation, but electroporation significantly decreased cell viability compared with controls, while 
combination (electroporation + PS) labelling significantly improved cell viability (Table 1). This 
combination labelling was also fast (i.e., 30 min), obviating the need for prolonged incubation by 
transfection agents, i.e., overnight (see Table 1 for comparison). 
2.2. Assessment Cellular Iron Uptake and Spatial Distribution  
The standard optical density (OD) curve in a 96-well plate using the Quantichrom iron assay was 
plotted (Figure 2). This had a slope of 0.0005 with R2 = 0.9996. Using Equation (3) (described in 
Experimental Section), the amount of intracellular iron was estimated to be 3.773 ± 0.348 (n = 4) for 
the A375M cell line and 4.115 ± 0.564 (n = 4) for the MCF7 cell line (Table 2). 
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Figure 2. Standard curve in 96-well plate assay.  
 
Table 2. Quantitative cellular iron uptake: labelled with IO-nPs (ferumoxides) using PS/EP 
and measured by the Quantichrom iron assay (PS, protamine sulphate; EP, electroporation). 
Iron uptake Labelled (pg/cell) Control (pg/cell) 
A375M (melanoma) 3.773 ± 0.348 (n = 4) 0.075 ± 0.130 (n = 4) 
MCF7 (breast) 4.115 ± 0.564 (n = 4) 0.179 ± 0.229 (n = 4) 
The spatial distribution of SPIOs following cellular uptake was demonstrated by stained optical 
images (Figure 1) and can be observed more closely in the accompanying MFM images (Figures 3 and 4). 
Cells can be observed in their morphological images in Figure 3a for a labelled cell and for an 
unlabelled (control) cell in Figure 3c. The uptake of SPIOs uptake is clearly shown in the phase 
(retrace) image (Figure 3b) for the labelled cell, while no such phase shift was detected in the control 
cell (Figure 3d).  
Figure 3. Magnetic force microscopy (MFM) images showing nanoparticles’ uptake and 
spatial distribution within single cells: (a–b) a labelled cell with morphological images in 
(a) and SPIOs uptake and a spatial distribution in phase (retrace) image (b); (c–d) an 
unlabelled cell for control with morphological images in (c), and no such phase shift 
detected in (d). 
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Figure 3. Cont. 
 
Figure 4. MFM images of a single cell: (a) 3D morphological image of the cell; (b) phase 
image in retrace mode (lift height of 100 nm from cell surface) showing SPIOs uptake and 
spatial distribution. 
 
SPIOs uptake by a single cell was observed using MFM (Figure 4), the quantitative iron uptake by 
the cell being estimated by Equation (5) (described in Experimental Section) at around 1.9 pg. The 
double-layer model provides an approximate iron uptake of 3.8 pg per cell.  
2.3. Discussion 
It is important to develop simple, accurate and low-cost methods for the determination of SPIOs 
iron for both clinical research and industrial work. The simplest iron determination method is the 
spectrophotometric one, which is based on protein precipitation, reduction of Fe3+ and formation of a 
coloured complex of Fe2+ with a chromogen [31]. The intensity of the colour, measured at 590 nm by 
spectrophotometry, colorimeter or a microplate reader being directly proportional to the iron concentration 
in the sample. 
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Iron content within in vitro labelled cells was evaluated using the Quantichrom iron assay.  
Wu et al. [32] reported that when 50 µL of samples containing 106 cells were mixed with 200 µL 
Quantichrom Working Reagent in a 96-well plate (in triplicate) and incubated at room temperature 
overnight, the iron content per cell increased from 0.32 pg (protamine only) to 0.84 pg (ferumoxides) 
and 26.0 pg (Fe-Pro complex) 2 h after cell labelling. 
The ferrozine-based assay is acknowledged as the most reliable method for colorimetric quantification 
of iron [22,24,26]. Ferrozine is an iron-chelating agent that forms a complex with ferrous iron (Fe2+) 
and exhibits characteristic UV-Vis absorption at 562 nm. The amount of intracellular iron as 
determined by the ferrozine-based colorimetric assay ranges between 1 and 5 pg Fe/cell, depending on 
the electroporation pulse conditions [22]. A more detailed description of colorimetric ferrozine-based 
assay can be found in [33]. This sensitive assay permits the quantification of iron in cultured cells in 
amounts ranging between 0.2 and 30 nmol. More importantly, estimates of cellular iron content 
obtained with the ferrozine-based assay are similar to those determined by the more expensive atomic 
absorption spectroscopy, MR relaxometry and radioactive detection, described below. 
Atomic spectrometry: Inductively coupled plasma-atomic emission spectrometry (ICP-AES),  
also referred to as inductively coupled plasma optical emission spectrometry (ICP-OES), is a  
well-established technique for elemental analysis. For cellular iron uptake determination, the technique 
is based on the measurement of the emitted light of excited iron atoms. In the quantitative 
determination of intracellular iron uptake by human lung carcinoma cells (CLL-185) [8] by ICP-AES 
revealed a dose-dependent increase of iron oxide uptake (1.69 μg ± 0.11 Fe per 100,000 cells at  
1.0 mg Fe/mL vs. 0.08 μg ± 0.01 Fe per 100,000 cells at 0.01 mg Fe/mL; p < 0.05) (Table 3). 
Inductively coupled plasma-mass spectrometry (ICP-MS) is an analytical technique that measures the  
mass-to-charge ratio of charged particles. Different chemicals have different masses, and this fact is 
used in mass spectrometry to identify chemicals present in a sample. The cellular uptake of micro-sized 
iron oxide particles analysed [19] by ICP-MS was reported to be 35 pg of Fe/cell (Table 3), which is 
consistent with results obtained by microscopy. Another clinically used paramagnetic contrast agents 
(apart from iron oxide based particles) is gadolinium (Gd)-based chelates, and the intracellular 
concentration of Gd per cell can also be measured using ICP-MS [34]. 
Magnetic resonance (MR) relaxometry: MR relaxometric methods are also used to measure the 
concentration of iron. They are based on the linear relationship between iron content and MR 
relaxation rates of 1/T1 or 1/T2 [24,26]. By using either custom designed equipment or commercially 
available MRI scanners, T1 and T2 relaxation rates obtained from samples are compared with the 
known iron concentration in serial dilutions of iron solution that is used for generating standard 
calibration curve. Bulte et al. [24] estimated cellular uptakes of 9.3 ± 4.3 and 13.6 ± 5.5 pg iron/cell for 
the CG-4 (rat oligodendrocyte progenitor) and HeLa (human cervix carcinoma) cells, respectively. 
This was in agreement with the corresponding values obtained using the Ferrozine assay, which was 
8.5 ± 2.0 and 13.6 ± 2.9, respectively (Table 3). 
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Table 3. Reported cellular uptake rates of iron. 
Measurement Uptake (pg Fe/cell) Cells # Magnetic particles & labelling * References 
ICP-AES 16.9 ± 1.1 CLL-185 SPIOs (1 mg/mL) and lipofection [8] 
ICP-AES 0.8 ± 0.1 CLL-185 SPIOs (10 µg/mL) and lipofection [8] 
ICP-MS 35 B16F10 MPIO beads and macrophages [19] 
MR relaxometry 9.3 ± 4.3 CG-4 SPIOs (1–25 µg/mL) and dendrimers [24] 
Ferrozine assay  8.5 ± 2.0 CG-4 SPIOs (1–25 µg/mL) and dendrimers [24] 
MR relaxometry 13.6 ± 5.5 HeLa SPIOs (1–25 µg/mL) and dendrimers [24] 
Ferrozine assay 13.6 ± 2.9 HeLa SPIOs (1–25 µg/mL) and dendrimers [24] 
Relaxometry/Ferrozine 3.8 ± 1.2 CG-4 Ferumoxides and PLL (25 µg/mL) [26] 
Gamma counter and 111In 10 to 30 CD34+ CLIO-Tat peptides (100 µg/mL) [20] 
Ferrozine assay 1 to 5 NSC (C17.2) Ferumoxides (2 mg/mL) and EP [22] 
Quantichrom assay 26.0 Leukocytes Ferumoxides (50 µg/mL) and PS [32] 
# Cell lines used in in vitro measurement—B16F10: melanoma; CLL-185: human lung carcinoma cells; CG-4: rat 
oligodendrocyte progenitor; HeLa: human cervix carcinoma; CD34+: human hematopoietic cells; MSC: mesenchymal 
stem cells; NSC (C17.2): neural stem cells. * Labelling method—EP: electroporation; PS: protamine sulphate; ICP-AES, 
inductively coupled plasma-atomic emission spectrometry; ICP-MS, inductively coupled plasma-mass spectrometry. 
Radioactive detection: In this technique, Dextran-coated SPIO are modified with diethylenetriamine 
penta-acetic acid (DTPA) for isotope labelling, i.e., using a radiotracer (111In). The radiolabeled  
cross-linked iron oxide (CLIO)-TAT particles, counted with a gamma counter, result in labelling 
efficiencies ranging [20] from 10 to 30 pg of superparamagnetic iron per cell (Table 3). Our in vitro 
study suggests that electroporation in the presence of protamine sulphate (PS) as a transfection agent can 
provide an effective and fast technique for labelling various types of cells with magnetic nanoparticles 
and provides a method that can be used clinically. Our quantitative results obtained by the 
Quantichrom iron assay (3.8 to 4.1 pg per cell) are in good agreement with the values in the published 
literature (i.e., from 0.8 to 35 pg/cell, Table 3), depending on cell types, SPIOs size and concentration, 
surface modification, incubation time, etc. The MFM imaging data demonstrate the spatial distribution 
of internalized IO-nPs. Furthermore, with the simplified geometrical model, the MFM-based single 
cell imaging assessment of IO-nPs’ uptake can provide additional quantitative information on the 
individual magnetized cell (1.9 to 3.8 pg). More advanced modelling and simulation would provide 
more accurate quantitative information of single-cell magnetization based on MFM scanned image and 
other imaging modality, such as TEM, to estimate SPIOs’ aggregation depth inside the cell [30]. 
Finally, magnetofection is a relatively new transfection method and is achieved by the application 
of a magnetic field to superparamagnetic iron oxide particles [35]. Magnetofection exploits the 
magnetic forces that guide the SPIOs, associated with gene vectors, DNA plasmids, toward the target 
cells. The presence of these magnetic fields increases the transfection efficiency, compared to cells not 
exposed to the magnetic field [35–39]. Further investigation with magnetic nanoparticles coated with 
positively charged groups [40] for more cell labelling experiments, especially with the used of the  
our recently reported magnetoporation method [41] by an low-intensity external rotating magnetic 
field, is underway, since magnetoporation/magnetofection have potential over electroporation in 
clinical applications.  
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3. Experimental Section 
3.1. Cell Labelling by Magnetic Nanoparticles  
We investigated different magnetic cell labelling methods using magnetic nanoparticles (SPIOs or 
IO-nPs), including transfection agents and electroporation. Our aim was to identify an effective and 
fast technique for potential clinical use. The work was based on the hypothesis that SPIOs, coated and 
mixed as complexes with cationic transfection agents, can be more effectively aligned to cell 
membranes, as these are slightly negatively charged, thereby achieving more efficient labelling 
through trans-membrane passage by electropermeabilization and other mechanisms, including natural 
endocytosis. Several human cancer cell lines (A375M, DLD1, MCF7, SW480 and U2OS) were used 
for the labelling studies. 
3.1.1. Labelling with Transfection Agent (PS) 
The transfection agent, protamine sulphate (PS), at varying concentrations was mixed with IO-nPs  
(60 g/mL) in culture media for 15 min at room temperature with intermittent hand shakings. The 
culture medium containing the transfection agent-IO-nPs complexes were added to the cell cultures 
such that the final concentration of IO-nPs was 30 μg/mL, and the final concentrations of PS ranged 
between 1.0–5.0 μg/mL in cell viability experiments and 3.0 μg/mL for other experiments. Cells were 
then incubated overnight, for approximately 16–18 h. 
3.1.2. Labelling with Electroporation 
Electroporation was performed with a Nucleofector Device II from Amaxa Biosystems GmbH 
(Cologne, Germany), according to the manufacturer’s instructions. Cells suspended in Nucleofector 
Solutions were mixed with IO-nPs media before transfer to electroporation cuvettes. Specific 
intensities and lengths of electric pulse were selected and used to obtain optimal labelling. Control 
experiments were performed by processing cells in the same way, but in the absence of IO-nPs. After 
electroporation, cell suspensions were diluted with pre-warmed complete DMEM and transferred to 
culture plates. The final concentration of IO-nPs in culture medium was 100 μg/mL. Cells were 
incubated overnight or immediately assessed for instant labelling or cell viability. 
3.1.3. Labelling with Electroporation in the Presence of PS 
This was carried out by the same procedure and addition of PS-IO-nPs complexes to the  
pre-warmed medium used to dilute the electroporation mixtures. In order to maintain comparable 
conditions, the final concentrations were kept at 3 μg/mL and 100 μg/mL for PS and IO-nPs, respectively. 
3.2. Assessment of Magnetically Labelled Cells 
3.2.1. Cell Viability by MTS Assay 
The MTS Cell Titre 96 AQueous One Solution Cell Proliferation Assay (Promega, Southampton, 
UK) was used to determine cell viability in control and treated cell studies. Cells were seeded at 
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densities of 5000–10,000 cells/well in 96-well plates and were either assayed at 30 min  
(after electroporation) or left to adhere for 16–18 h for transfection treatments before MTS assay. The 
MTS assay values (absorbance at 490 nm) were expressed as the percentage of that of the 
corresponding control cells. 
3.2.2. Prussian Blue Staining for Assessing Labelling Efficiency 
Cells grown on glass coverslips were washed with PBS to remove excess of IO-nPs and fixed with 
4% para-formaldehyde for 30 min. They were then washed with ddH2O and incubated for 30 min with 
2.5% potassium ferrocyanide in 2.5% HCl following counterstaining with nuclear fast red for 5 min. 
The samples were examined using a Zeiss microscope Axiovert 200 (Zeiss, Oberkochen, Germany) at 
×40 and ×63 magnification and Axiovision 4.6 software. Cells were considered Prussian Blue positive 
if intra-cytoplasmic blue granules could be identified. The efficiency of cell labelling was determined 
by manual counting of Prussian Blue-positive and -negative cells. The percentage of labelled cells was 
determined from the average of 5 to 10 fields (×40). 
3.2.3. Quantitative Colorimetric Iron Assay 
The Quantichrom iron assay (BioAssay Systems, Hayward, CA, USA), a quantitative colorimetric 
iron determination at 590 nm, was used for studying cellular iron uptake. In accordance with the 
manufacturer’s protocol, 50 µL of standards or samples containing 106 cells were mixed with 200 µL 
Quantichrom Working Reagent in a 96-well plate and incubated at room temperature overnight [32].  
In this system, the optical density (OD) at 590 nm measured by a microplate reader is directly proportional 
to the iron concentration in the sample. The OD against standard iron concentrations were plotted by 
subtracting blank (water) OD from the standard OD values, and the slope of the data plot then 
determined using liner regression fitting (Slope = 0.0005, see Figure 3). The iron concentration 
(ICsample in µg/dL) of the labelled sample can be calculated as: 
Slope
ODOD
IC blanksamplesample
  (1) 
where ODsample and ODblank are OD590nm values of the labelled cell suspension sample and the blank 
water sample. Given cell concentration (CCsample) in the labelled cell suspension sample of N (cell/dL) 
(N = 106 cells/(50 µL + 200 µL) in this assay), averaged iron uptake per cell (iron uptake in pg/cell) 
can be obtained from: 
6blanksample
sample
sample 101
Slope
ODOD
CC
IC
IronUptake
N
  (2) 
3.3. Magnetic Force Microscopy (MFM) Observation and Assessment 
3.3.1. Magnetic Force Microscopy (MFM) Principle 
MFM is a special mode of operation of the non-contact scanning atomic force microscope (AFM), 
with high (~25–50 nm) spatial resolution [28,29]. The principle of MFM is to measure the change of 
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the interaction force (Fm) between a magnetized probe (of strength H) and the local stray magnetic 
field (induction), B, from the sample as the probe is scanned across the surface in dynamic  
(non-contact) mode by : 
 (3) 
where m = MV is the magnetic moment on a volume, V, of the material with magnetisation of M  
(M = χH and χ is material’s volumetric magnetic susceptibility, which can be obtained SPIOs’ material 
magnetization curve), and each individual atomic moments in the material contribute to its overall 
magnetic induction (B) response as: 
 MHB  0μ  (4) 
where μ0 is the permeability of free space.  
One standard method of obtaining a MFM image is to operate the AFM in close-contact mode with 
a magnetic cantilever that detects a force gradient, which contains information from both the surface 
structure and the local magnetic field. After collecting a topographic image close to the surface, the 
cantilever is then ‘raised’ some height above the surface, where the magnetic forces dominate on the 
reverse scan. Signals from surface topography dominate at close distances to the surface, while at 
greater distances from the surface, the magnetic signal dominates. Consequently, depending on the 
distance between the surface and the tip, normal MFM images may contain a combination of topographic 
and magnetic signals. Standard magnetic recording tape was used to obtain known magnetic domain 
pattern image for assisting selection of the MFM tip lift height (e.g., 100 nm in this study). 
3.3.2. MFM Scans with Image Processing for Single Cell Assessment 
IO-nPs labelled cells (SW480) were prepared, and the air dried glass slides of samples were used 
for MFM. Cell uptake was imaged using a JPK Nanowizard atomic-force microscope (AFM) (JPK 
Instruments, Berlin, Germany) on top of an Axiovert 200 inverted microscope (Carl Zeiss, Jena). 
MFM imaging using phase detection was performed in hover (lift) mode within intermittent contact 
(dynamic) mode. The lift height was 100 nm distance between the cantilever tip and the surface of the 
sample, and the MFM scan was performed at a scan rate of 1 Hz with a resolution of 512 × 512 pixels. 
The MFM cantilevers were made of silicon coated with cobalt-chromium alloy (Hc = 300–400 Oe, 
spring constant: 1–5 N/m, MFMR-10, Nanosensors Inc., Darmstadt, Germany). 
MFM scan image of SPIOs uptake with a complete single cell was then further processed by a 
custom-written Matlab (MathWorks, Cambridge, UK) codes for imaging analysis to obtain a total 
SPIOs’ area ASPIOs. To assess the SPIOs’ uptake within the image, a simplified SPIO single-layer 
geometrical model was used to obtain the SPIOs’ volume V (V = ASPIOs × DSPIO, where DSPIO is the 
diameter of a single SPIO particle). Given a volumetric density, ρ, of the used SPIOs, we could 
estimate the mass MSPIOs of the uptake SPIOs by: 
SPIOsM V  (5) 
where ρ = 6000 kg/m3 [42]. A double-layer model can also be used to estimate SPIOs’ aggregation 
inside the cell [30].  
  
)( BmFm 
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4. Conclusions 
This in vitro study indicates that electroporation in the presence of the clinically used transfection 
agent, protamine sulphate (PS), can provide an effective and fast technique for labelling of various cell 
types with magnetic nanoparticles (e.g., ferumoxides, a clinical proved SPIOs). The Quantichrom iron 
assay provides a simpler method for iron determination in vitro, compared to atomic spectrometry,  
MR relaxometry and radioactive detection. The MFM scan provides an unique method for observing 
any (not just iron-based) cellular uptake of magnetic particles ranging from the nano-meter up to  
100 micro-meter scale, and further quantitative information of individual cells can be derived from 
image processing using simple or complex models.  
Electro-magnetoporation can provide an efficient tool for potential in situ clinical use by which  
in vivo quantification of cell/tissue iron uptake can be obtained by MR relaxometry in addition to 
tracking of the labelled cells by MRI.  
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